Voluntary announcement - HX9428 latest data from Phase I and Phase II clinical studies for the treatment of neovascular age-related macular degeneration (nAMD)
Filed with HKEX · Stock code 2637 · · 3 pages · English
Fujian Haixi Pharmaceuticals Co., Ltd. 福建海西新藥創制股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 2637) VOLUNTARY ANNOUNCEMENT ## HX9428 LATEST DATA FROM PHASE I AND PHASE II ## CLINICAL STUDIES FOR THE TREATMENT OF NEOVASCULAR ## AGE-RELATED MACULAR DEGENERATION (nAMD) This announcement is made by Fujian Haixi Pharmaceuticals Co., Ltd
Fujian Haixi Pharmaceuticals Co., Ltd. on 6ix
Earlier from Fujian Haixi Pharmaceuticals
- Fujian Haixi Pharmaceuticals Says US FDA Approves IND Application Of HX9428
- Fujian Haixi Pharmaceuticals Nominates Chen Tingze As Candidate For Executive Director
Later from Fujian Haixi Pharmaceuticals
- Interim report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - progress update on purchases of h shares pursuant to the share incentive scheme
Follow Fujian Haixi Pharmaceuticals into a list and get an email when it puts out news.
Follow Fujian Haixi Pharmaceuticals